Event Title: 2nd Proteome- Targeted Drug Discovery Summit

ID: 23255

2nd Proteome- Targeted Drug Discovery Summit
Hanson Wade
The Westin Boston Waterfront, 425 Summer Street, 02210
United States
Event Type
Date of event
16 Nov 2020
on Monday November 16, 2020 at 8:30 am (ends Wednesday November 18, 2020 at 5:00 pm)
Who should attend?
Fees (link)
Earlybird Registration: Conference + Workshop USD 2748.00 Earlybird Registration: Conference Only USD 2299.00 Standard Rate: Conference + Workshop USD 3498.00 Standard Rate: Conference Only USD 2899.00
CPD/CME Points
Summary of event
Leverage Next Generation Structural & Biochemical Tools to Identify Novel Targets & Optimise Structure-Guided Small Molecule Discovery to Drug the Entire Proteome
Speakers: Anup Upadhyay, Principal Research Scientist I, AbbVie, Benjamin Ruprecht, Associate Principal Scientist of Chemical Biology, Merck, Christopher Browne, Senior Research Scientist, AstraZeneca, Christopher Dimitri, Investigator, GSK, Dave Wustrow, SVP of Discovery & Pre-Clinical Development, RAPT Therapeutics, Douglas Johnson, Senior Director of Chemical Biology & Proteomics, Biogen, Evris Gavathiotis, Professor of Biochemistry & Medicine, Albert Einstein College of Medicine, Grahame McKenzie, Chief Scientific Officer, Phoremost, Holly Soutter, Director of Biophysics & Biochemistry, Silicon Therapeutics, Jenny Viklund, Director of Protein Science & Drug Design, Sprint Bioscience, Kristin Riching, Senior Research Scientist, Promega, Mario Niepel, Associate Director, Ribon Therapeutics, Nathan Fuller, Director of Chemistry, Alkermes, Nick Shah, Head of In Vitro Pharmacology, DiCE Molecules, Nir London, Senior Scientist, The Weizmann Institute of Science, Thomas Smith, Senior Investigator, Novartis, William Pomerantz, Associate Professor of Chemistry, University of Minnesota
How to register
Tickets https://go.evvnt.com/587450-0?pid=5366 Brochure https://go.evvnt.com/587450-2?pid=5366 Website https://go.evvnt.com/587450-3?pid=5366 Contact: Jenna Warren, Divisional Head of Marketing, info@hansonwade.com, (+1) 617 455 4188
Additional Information
Finally Drugging The "Undruggable" Proteome With about 85% of the proteome currently undrugged, accessing these targets that are, at present, extremely difficult to drug, has prevented researchers from achieving desired clinical successes. The 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech, as well as key opinion leaders in academia, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency, selectivity, and physio-chemical properties. Join the pioneering directors, team leaders and senior scientists from the biopharmaceutical industry and academia to enhance your existing structural, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline.
Programme/Speakers (attachment): No attachment